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a  b  s  t  r  a  c  t
Small  molecule  pharmaceutical  products  are  assumed  to reach  concentrations  in  semen  similar  to  those
in blood  plasma.  Exposure  modeling  for  these  small-molecule  products  in  humans  assumes  a  daily dose
of 5  mL  of semen  and  100%  absorption  from  the  vagina  with  distribution  to the  conceptus  through  the
maternal  systemic  circulation.  Monoclonal  antibody  drugs  are  present  in  semen  at  concentrations  about
2%  or less  of those  in  blood,  and  the  modeling  used  for  small  molecules  will  over-estimate  the  possibility
of  conceptus  exposure  to  immunoglobulins.  It is  not  known  whether  peptide  products  reach  semen,  but
in general  peptide  medications  are  destroyed  by  vaginal  peptidases,  and  conceptus  exposure  is  predicted
to  be minimal.  Theoretical  exposure  routes  to pharmaceuticals  that might  result  in  exposure  of  the  con-
ceptus  greater  than  that  of maternal  systemic  exposures  include  direct access  through  the cervical  canal,
adsorption  to sperm  for carriage  into  the  oocyte,  and  direct delivery  from  the  vaginal  veins  or lymphatics
to  the uterine  artery.  There  is some  evidence  for direct  access  to  the  uterus  for progesterone,  terbutaline,harmaceuticals and  danazol,  but  the  evidence  does  not  involve  exposures  during  pregnancy  in most  instances.  Studies
in  mice,  rats,  rabbits,  and  monkeys  do  not  suggest  that exposure  to small  molecule  pharmaceuticals  in
semen  imposes  risks  to  the conceptus  beyond  those  that  can  be  predicted  using  modeling  of  systemic
maternal  exposure.  Monoclonal  antibody  and  peptide  exposure  in semen  does  not  pose  a signiﬁcant  risk
to the  conceptus.
©  2015  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Semen is a mixture of spermatozoa produced in the testicular
eminiferous epithelium and seminal ﬂuid originating from the epi-
idymis, seminal vesicles, prostate, and to a lesser extent, other
ale accessory glands. Concern about the presence of pharma-
euticals (both small and large molecules) in semen and their
ransport to sexual partners has been reﬂected in recommenda-
ions or requirements that men  receiving certain pharmaceutical
roducts use condoms during sexual activity [1–3]. These recom-
endations have come from industry authors [1], the European
nion Heads of Medicines Agency [2], and the U.S. Food and
rug Administration, which also provided guidance on quantitative
ssessment of risk [3]. Although there are concerns about potential
rug toxicity in sexual partners of treated individuals, the possi-
le transfer of pharmaceuticals to the developing conceptus is the
redominant consideration when condom use is recommended,
articularly during clinical trials with new pharmaceutical prod-
cts when potential effects on gametes or the conceptus are not
et fully investigated.
Possible mechanisms of seminal transfer of pharmaceutical
roducts and other chemicals have been reviewed, most recently
n 2005 [4]. Since that publication, additional research has become
vailable to inform risk assessment when considering possible con-
eptus exposure to pharmaceuticals or other chemicals in semen.
ome of the additional research has been performed by a con-
ortium of members of the Health and Environmental Sciences
nstitute (HESI) Developmental and Reproductive Toxicology Tech-
ical Committee [5]. The present review paper was  prepared by
n expert group coordinated by HESI and summarizes the current
nderstanding of the potential for seminal transfer of pharma-
euticals to female gametes, the developing embryo, and fetus.
he possible role of male exposures on transmissible genetic or
pigenetic alterations of sperm chromatin and possible effects of
harmaceutical exposure on sperm function will not be consid-
red here, although in the absence of speciﬁc transport mechanisms
arge peptides and proteins are not expected to enter the cell and
nteract with cellular DNA to pose a genotoxic risk [6,7].
. Components of semen
The role of semen is to deliver spermatozoa to the female genital
ract. Semen ejaculated into the vagina coagulates immediately and
iqueﬁes again after approximately 20 min, allowing spermatozoa
o enter the cervix from which they are released to the uterine cav-
ty and fallopian tubes [8]. By contrast, semen gains direct access
o the uterine cavity in some other species including rat, pig, and
orse [9,10]. Mammalian spermatozoa develop in the seminifer-
us tubules of the testis and undergo additional maturation duringFig. 1. Components of human semen.
transit through the epididymis, which also stores spermatozoa.
The epididymis gives rise to the vas deferens, which transmits
spermatozoa. Behind the bladder, the vas deferens and seminal
vesicles join to form the ejaculatory duct, which opens into the
urethra at the base of the prostate gland the ﬂuid of which is mixed
with spermatozoa and seminal vesicle ﬂuid to form semen.
The volume of human ejaculate ranges from 2.3 to 5.0 mL, with
an average of 3.4 mL  (review of 30 studies by Owen and Katz [11]).
Spermatozoa make up only a small portion of whole human semen,
i.e., 1–5% of the total volume [12]. The testicular contribution to
semen volume is minimal (Fig. 1). The so-called blood–testis bar-
rier consists of tight junctions between Sertoli cells proximal to the
spermatocytes, limiting access of blood-borne chemicals to post-
mitotic germ cells and to the lumen of the seminiferous tubules.
Because most of the seminal volume originates from the seminal
vesicles and prostate, partition of pharmaceuticals to these glands
is more important than is testicular access in inﬂuencing semen
concentration.
Seminal plasma components have nutritive, buffering, and pro-
tective functions for the spermatozoa. The contributions from the
different accessory glands and the composition of the seminal
plasma differ to some degree between different species. In the
human, 65–75% of semen originates from the seminal vesicles
(Fig. 1), and constituents include acid phosphatase, citric acid,
inositol, calcium, chloride, magnesium, zinc, potassium, sodium,
fructose, glucose, ascorbic acid, and prostaglandins. As the semen
passes through the prostate, alkaline prostatic ﬂuid is added, com-
prising about 25–30% of semen. The buffering capacity of this ﬂuid
protects sperm in the acidic vaginal environment until the sperm
gain access to the cervical mucus. Proteins and amino acids are also
present in seminal plasma, and albumin constitutes approximately
one-third of the total protein concentration in semen [11].
The pH of human semen is a matter of some debate, and there
is considerable variation in the pH measurements reported by dif-
ferent researchers. Nevertheless, the pH of semen lies generally
slightly above neutral with a reported range of 7.4–8.4 (reviewed
by Owen and Katz [11]). Semen has buffering capacity much higher
than that of most other body ﬂuids and maintains its pH near
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eutral even in the acidic vaginal environment, providing the
permatozoa with the opportunity to enter the neutral pH envi-
onment of the cervical mucus.
. Vaginal and cervical enzymes
Enzymes in the vagina and in cervical mucus have been
escribed, some of which are involved in protein degradation, espe-
ially aminopeptidases (i.e., exopeptidases). While no in vivo data
n the approximate rate of protein degradation in the vagina could
e identiﬁed, studies on vaginal homogenates show that the enzy-
atic activity of aminopeptidases is similar in rats, rabbits, and
umans, with N-aminopeptidases exhibiting the highest activity
13]. Enzyme activity also varies with the menstrual cycle [14].
Human tissue kallikrein-related peptidases are expressed
hroughout the female reproductive system, including in cervico-
aginal ﬂuid. Kallikrein-related peptidases are localized in the
landular epithelium of the fallopian tubes and endometrium, the
ervical mucus-secreting epithelium, and vaginal stratiﬁed squa-
ous epithelium, and their concentrations peak in cervico-vaginal
uid after ovulation [15]. Kallikrein-related peptidases are also
ecreted in the male prostate gland and cleave C-terminals of pro-
eins to several amino acid residues to enhance the liquefaction of
jaculated semen in the female reproductive tract [16].
Insulin can be considered as an example peptide drug. Endopep-
idases might play an important role in insulin degradation,
ecause in vitro degradation of insulin in small intestinal mucosal
omogenates is rapid, and the presence of protease inhibitors
educes degradation considerably. The in vivo hypoglycemic
esponse and pharmacological availability of insulin administered
irectly into the small intestine is insigniﬁcant [17]. Insulin is
hought to be hydrolyzed by endopeptidases [18], and the proteo-
ytic degradation of insulin in the vagina is comparable to that in
he ileum [19,20], supporting the assumption that bioavailability of
nsulin, and most likely also other peptides, via vaginal absorption
s negligible.
. Risk assessment based on systemic distribution
It is standard practice to assume that any pharmaceutical
resent in the circulation of a man  will gain access to his semen.
hen seminal concentrations of the pharmaceutical are available,
his default assumption can be modiﬁed. In the absence of data
n seminal concentration of a pharmaceutical, it can be assumed
hat at most, seminal concentrations of small molecular weight
harmaceutical compounds will be an order of magnitude higher
han blood, plasma, or serum concentrations. This assumption is
ased on the empirical observation that semen:blood concentra-
ion ratios were 11 or less for most reported chemicals [4]. An
xception was chromium, which was measured in an even higher
oncentration in semen from some metalworkers; however, the
uthors of that report could not exclude environmental contami-
ation of the specimens after collection [21]. For large molecular
eight drugs such as monoclonal antibodies, the concentrations
ound in semen are much lower than plasma concentrations [22].
To estimate a worst case exposure of a woman to low molecular
eight pharmaceuticals in semen, the amount in a 5-mL ejaculate
an be assumed to be 100% absorbed every day. The volume of dis-
ribution can be used to calculate the concentration of the chemical
n the woman’s blood, although the FDA draft guidance recom-
ends considering distribution in a 5000-mL blood volume. Evenor molecules that are concentrated in semen, the resulting con-
entration in the woman’s blood is typically three or more orders
f magnitude less than the concentration of the chemical in the
lood of the man  who provided the semen [4]. The concentrationxicology 59 (2016) 22–30
calculated for the woman’s blood can be assumed to be available to
a developing conceptus, and a comparison can be made to concen-
trations that have been identiﬁed as potentially harmful in clinical
or non-clinical studies.
As an example of such a calculation for thalidomide, the maxi-
mum  plasma concentration in a man  after an 800-mg dose (twice
as high as the recommended maximum clinical dose) is 4420 ng/mL
[23]. Consistent with draft FDA guidance, this concentration can be
assumed to be present in semen [3]. A 5-mL “dose” of semen would
contain 4420 × 5 = 22,100 ng of thalidomide. Vaginal absorption of
the entire amount and distribution in a 5000-mL maternal blood
volume would produce a maximum concentration of 4.42 ng/mL.
The maximum concentration of thalidomide in rabbit plasma at
the no observed adverse effect level is 824 ng/mL [24], giving a pre-
dicted human exposure multiple of 186 for thalidomide exposure
in semen. According to the FDA draft guidance, no further evalua-
tion would be required. However, this exposure multiple is much
lower than the >4000-fold obtained by using actual human seminal
concentration of 1000 ng/g after a 400-mg thalidomide dose [25],
semen weight of 4 g, a volume of distribution of 16,000 mL, and
100% absorption as detailed in the publication by Hui et al. [26], so
the recommended procedure for exposure estimation in this case
would be highly protective.
For large-molecule drugs including monoclonal antibodies, this
modeling will markedly overestimate possible conceptus exposure,
given the low concentration in semen, ≤2% of serum [22,27] and/or
the limited vaginal absorption, 3.5–4 orders of magnitude below
intravenous absorption [22,28]. For immunoglobulins, access to
the embryo has been demonstrated to be very low during the ﬁrst
trimester [29,30]. These considerations are discussed below.
5. Other exposure routes to the conceptus
Besides absorption of chemicals from semen across the vaginal
epithelium into the maternal systemic circulation, access to the
conceptus might in theory be possible by three other mechanisms:
migration of the chemical through the cervical canal, carriage by
the fertilizing spermatozoon into the oocyte, and transport from
vaginal venous or lymphatic drainage to the uterine artery through
a so-called counter-current mechanism. There are data to address
each of these potential mechanisms as discussed below.
5.1. Access through the cervical canal
5.1.1. The non-pregnant cervical canal
The cervical canal contains mucus produced by endocervical
glands (reviewed by Becher et al. [31]). Properties of the mucus
change during the menstrual cycle and are affected by estrogen and
progesterone. The estrogen-dominated mucus at mid-cycle can be
penetrated by sperm for several days prior to ovulation when the
mucus is well hydrated, but during the luteal phase dominated by
progesterone, the mucus is less hydrated and constitutes a bar-
rier to the passage of sperm [32]. Carbohydrate accounts for about
80% of the mucus by weight and consists of oligosaccharides that
protect a protein core (reviewed by Carlstedt and Sheehan [33]).
The basic subunit of the mucus consists of 3–5 oligosaccharide-
rich regions ﬂanking a 400-amino acid naked protein region, with
about 10 subunits in a linear array making up a ﬁlament of mucus
[34]. These glycoprotein ﬁlaments form a meshwork that makes up
the structural elements of the mucus plug.
Although it is possible that large molecules are blocked by
restricted space between the meshwork of glycoproteins that make
up the nonpregnant and pregnant mucus plug, the mesh spacing
of human mucus from the cervix and other locations has been
reported to be 90–3000 nm, which is large enough to permit the
A.R. Scialli et al. / Reproductive Toxicology 59 (2016) 22–30 25
Fig. 2. Reproductive tract of pregnant rats (a) 15, (b) 120, and (c) 240 min  aft
Table 1
Vital dyes administered vaginally to rats prior to coitus (from Thompson et al. [38]).
Dye Molecular weight (Da) Log P
Toluidine blue 374 0.9
Acid blue 40 473 −0.46
Acid blue 29 616 −5.65
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fBrilliant green 483 2.02
Sudan black B 457 8.81
assage of immunoglobin G (IgG) and many globular proteins
reviewed by Olmsted et al. [35]). The use of ﬂuorescent probes in
amples of human preovulatory cervical mucus showed in vitro the
iffusion of virus-like particles (38 and 55 nm) and proteins from
0 to 160 kDa (lysozyme, myoglobin, pepsin, amylase, lactoferrin,
gGs, IgAs) through mucus occurred as readily as diffusion through
aline. Diffusion of IgM (950 kDa) and polystyrene microspheres
59–1000 nm)  was impeded [35]. Because this preovulatory cer-
ical mucus was more hydrated than mucus at other times during
he menstrual cycle and during pregnancy, these ﬁndings might not
e informative about the permeability of mucus during pregnancy,
hich is not hydrated.
Another study used cervical-vaginal secretions pooled from
arious times during the menstrual cycle excluding the periovu-
atory period and identiﬁed mucus pore sizes of 50–1800 nm
sing non-mucoadhesive nanoparticles [36]. The authors proposed
hat interference with virus transmission through cervical mucus
as more likely based on adhesive interactions than steric hin-
rance. These coated nanoparticles have been evaluated primarily
s potential carriers for the delivery of pharmaceuticals through
ucus-coated tissues. It is not clear to what extent contamination
ith vaginal secretions altered the properties of cervical mucus
uring the collection process, which used a self-applied menstrual
ollection device.
Techniques for the measurement of drug transfer through
ucus have been reviewed [37]. Most studies have used experi-
ental animal gastric mucus or human ocular mucus. We are not
ware of studies involving the penetration of chemicals through
uman cervical mucus.
.1.2. The cervical canal during estrus and pregnancy
Additional investigation focused on whether chemicals applied
o the rat vagina prior to coitus gained access to the upper genital
ract [38]. Females were treated with intravaginal toluidine blue on
he afternoon of proestrus and cohabited with males overnight. No
ye was identiﬁed in the reproductive tract the following morning.
n a modiﬁcation of this experiment, female rats were treated with
ne of several vital dyes (Table 1) and cohabited with males for
35 min  with the room lights off. The males were removed and the
emales necropsied 30–60 min  later. Dye was found on the fur ofer intravaginal administration of toluidine blue (Thompson et al. [38]).
the male genital region and in the copulatory plug but not in the
female genital tract above the cervix. The vagina was stained by the
dyes with the exception of acid blue 29 (a protein stain) and sudan
black (a fat stain). This study suggested a lack of passage of small
molecules through the cervix during estrus, when the cervical canal
should have been at its most patent.
Studies have been performed in pregnant laboratory animals
to address the possibility of chemical transfer through the cervix.
Toluidine blue (molecular weight 270 Da; 0.5 mL)  was  administered
intravaginally to gestation day (GD) 12 rats [38]. The animals were
restrained in a head down position for 15 min  or monitored for leak-
age and licking behavior for 10 min  after dosing and were killed 15,
120, or 240 min  after dosing. The reproductive tract was removed,
visually inspected, and examined histopathologically. There was no
evidence of dye penetration past the cervix (Fig. 2). Similar results
were obtained using pregnant mice.
If a pharmaceutical product in the vagina were to pass through
the cervical canal into the uterine cavity during pregnancy, it is
not a foregone conclusion that the conceptus would be exposed.
The human blastocyst enters the uterus 3–4 days post-conception
and implants from 6 to 7 days post-conception into the decidua of
the uterus, where it becomes entirely buried beneath the uterine
epithelium by 9 days after conception. As the conceptus grows, the
overlying decidua bulges into the uterine cavity and is called the
decidua capsularis. By the end of the ﬁrst trimester, the decidua cap-
sularis meets and fuses with the decidua on the opposing uterine
wall, called the decidua parietalis, thereby obliterating the uter-
ine cavity. During the ﬁrst trimester the uterine cavity is a slit-like
space (Fig. 3). A pharmaceutical within the uterine cavity would
not have direct access to the conceptus but would need to diffuse
through the decidua and trophoblast to gain access to the amniotic
space and the embryo.
5.2. Transmission of chemicals to the upper female genital tract
and oocyte during coitus
In humans, semen deposited in the vagina in the days before
ovulation results in the rapid uptake of sperm by the cervical mucus,
from which the sperm are released over days into the upper gen-
ital tract. Of the hundreds of millions of spermatozoa deposited
in the vagina, typically ten to a few hundred sperm and on occa-
sion, up to one thousand sperm reach the fallopian tube [39,40].
Human seminal ﬂuid is believed to be excluded from the uterus
based on the observation that semen in the uterus causes cramping
and inﬂammation, attributed to seminal prostaglandins (reviewed
by Boomsma et al. [41]). By contrast, seminal proteins have been
identiﬁed in the uterus of the rat after coitus, although entry of
these proteins into the oviducts has not been documented [9]. The
access of seminal proteins and perhaps other seminal chemicals to
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he uterine cavity appears to be an important difference between
ats and humans.
The entry of a chemical into the human uterus or fallopian tube
fter vaginal application or exposure during coitus has not been
escribed. In a human subject, vaginal application of a gadolinium-
abeled spermicide in the mid-follicular phase of the cycle (about 6
ays prior to ovulation) resulted in identiﬁcation by magnetic reso-
ance imaging (MRI) of the label in the vagina and the endocervical
anal [42]. Studies using the same imaging technique reported the
aginal distribution of gel after simulated coitus using an artiﬁcial
enis or after real intercourse [43–48]. The images presented in
hese papers do not show label above the cervix, but the authors
id not comment on whether they evaluated the upper genital tract
or access of the gadolinium. Interpretation of the images is limited
y the bright signal from normal endometrium with the MRI  pro-
ocols used in these studies, but in no case was there continuity of
he signal with contrast in the vagina or endocervix.
It is clear, however, that human sperm are transported at mid-
ycle through the uterus to the fallopian tube within minutes after
eing deposited in the vagina [49]. This transport is independent
f sperm motility and has been attributed to uterine peristalsis, as
emonstrated by the transport of inert albumin spheres 5–40 m
n diameter [50]. Microorganisms also can ascend from the cervix
o the fallopian tubes as indicated by instances of salpingitis as a
onsequence of endocervical infection with gonorrhea or chlamy-
ia. Spread to the fallopian tubes of at least some of these infections
as been attributed to breakdown of the cervical mucus barrier at
he time of menses [51].
Some pharmaceuticals and other chemicals have been found
o bind to spermatozoa, raising the possibility of transfer to the
ocyte during fertilization. Rabbit, boar, and human spermatozoa
howed ultraviolet ﬂuorescence after incubation with tetracycline,
uggesting that the tetracycline in this in vitro exposure system had
ound to the spermatozoa cell [52]. The amount of binding was  not
uantiﬁed, and the fertilizing ability of the bound spermatozoa was
ot evaluated. In a male rabbit given radiolabeled thalidomide by
outh, the concentration of label in a washed ejaculated spermato-
oa sample was 0.05 g/mL when the blood concentration was
.81 g/mL and the seminal ﬂuid concentration was 9.60 g/mL,
ll expressed as thalidomide equivalents [53]. In a second rabbit,
permatozoa-associated thalidomide was 0.02 g/mL. Fertilizing
bility was not assessed but in another publication, mating and fer-
ility (number of pregnancies per number of rabbits that mated) of
ale rabbits were unaffected by oral treatment with thalidomide
p to 500 mg/kg/day [23]. Sperm motility, count, and concentra-
ion were also unaffected by thalidomide treatment. Cocaine added
o washed human spermatozoa was adsorbed with an estimated
600 binding sites per sperm cell [54]. Spermatozoa motility and
iability was not affected by incubation with cocaine at up tofter conception and line tracing of relevant structures.
670 M.  Assuming a human oocyte volume of 3.59 nL and a fertil-
izing spermatozoon carrying 3600 cocaine molecules, the resulting
concentration of cocaine in the oocyte would be 5 × 10−7 mg/L,
compared to a recreational adult blood cocaine concentration of
∼1 mg/L.
Spermatozoa concentrations of metals were measured in sam-
ples from men  working in a reﬁnery or polyoleﬁn factory in Finland
[55]. Mean spermatozoa metal concentrations in mg/kg of ashed
specimens were cadmium 0.003, lead 0.03, and aluminum 0.93.
These measurements were lower than in a group of healthy semen
donors, which the authors attributed to sound industrial hygiene
measures and the rural residence of the workers compared to the
urban residence of the semen donors. In the combined workers and
semen donors, there was  a negative association between sperm
or semen aluminum concentration and sperm motility. No other
measures of spermatozoa quality were associated with metal con-
centrations in spermatozoa or semen, and there were no estimates
of possible adverse effects of metal exposure on a fertilized oocyte.
In summary, where detailed analyses have been undertaken, it is
possible to detect some small molecule pharmaceuticals or chem-
icals on or within spermatozoa. However, where comparable data
exist, these concentrations are several log orders lower than plasma
concentrations.
5.3. Countercurrent transfer
Based on the demonstration in menopausal women that
vaginally administered progesterone has greater effects on the
endometrium than would be predicted based on systemic pro-
gesterone concentration, it has been suggested that there is a
countercurrent transfer mechanism whereby a chemical in the
vaginal venous or lymphatic efﬂuent can diffuse into the neighbor-
ing uterine arterial circulation [56]. This mechanism might result
in higher concentrations of a chemical in the uterine circulation
than in the systemic circulation. It has been shown in menopausal
women that vaginal progesterone administration results in nearly
two-fold higher progesterone concentrations in the uterine artery
than in the radial artery [57].
Although data from menopausal women  treated with pro-
gesterone might not apply to pregnant women  or to other
pharmaceutical products, the transfer of progesterone and terbu-
taline from the vagina to the uterus was  demonstrated in perfused
hysterectomy specimens obtained from premenopausal women
[58,59]. The preferential transfer of vaginally administered dana-
zol, which has a modiﬁed steroid hormone structure, to the uterus
and ovary of premenopausal women was inferred based on similar
tissue concentrations after hysterectomy in women given 100 mg
vaginally and women given 400 mg  orally in the face of much
lower serum concentrations after vaginal administration [60].
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Table  2
Human evidence for the preferential access of vaginal small molecules to the uterus.
Medication Model Findings Reference
Progesterone Functionally agonadal
women preparing for
embryo donation
Vaginal progesterone produced higher endometrial tissue
concentrations of progesterone than did intramuscular progesterone
in spite of higher serum progesterone concentrations after the
intramuscular administration
Miles et al. [74]
In vitro perfused
human uterus with
vaginal cuff
3H-progesterone placed on the vaginal cuff resulted in uptake of label
in  the endometrium and myometrium of the uterus beginning at 1 h of
perfusion and peaking at 5 h. Effects were greater in uteri removed
during the luteal compared to the follicular phase of the cycle
Bulletti et al.
[59]
Menopausal women
undergoing
hysterectomy
Uterine artery progesterone concentrations were higher than radial
artery progesterone concentrations
Cicinelli et al.
[57]
Terbutaline Pregnant women  Vaginal administration inhibited the contractions of premature labor
without systemic effects on blood pressure or heart rate and at very
low  systemic venous concentrations
Kullander and
Svanberg [61]
In vitro perfused
human uterus with
vaginal cuff
3H-terbutaline placed on the vaginal cuff resulted in uptake of label in
the  endometrium and myometrium of the uterus peaking at 12 h of
perfusion
Bulletti et al.
[58]
 and vaginal (100 mg)  medication produced comparable
terine tissue concentrations of the drug in spite of much
anazol concentrations after vaginal administration
Mizutani et al.
[60]
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erbutaline given during pregnancy also might reach the uterus
irectly from the vagina rather than systemically when used for
he treatment of preterm labor [61]. It is not known if this prop-
rty would apply to ﬁrst-trimester exposures. Thus, the possibility
f preferential transfer of a chemical from the vagina to the uterus
xists although it would require absorption through the vaginal
ucosa and has been demonstrated for few small molecule com-
ounds. Direct access through the cervix has not been excluded
s a contributor to this preferential distribution from the vagina
o the uterus. The evidence for such preferential distribution is
ummarized in Table 2.
. Empirical observations during mouse, rabbit, and
onkey pregnancy
.1. Small molecules
Possible alternative routes of exposure to chemicals in semen
ere evaluated in mice, rabbits, and monkeys. Because these
nimals will not mate when pregnant, test substances were admin-
stered vaginally rather than in semen.
Wild-type female mice mated to males carrying a transgene
ith a luciferase reporter produced embryos some of which carried
he transgene and could be identiﬁed by exposure to d-luciferin.
ntravaginal administration of d-luciferin during gestation resulted
n a visible signal indicating access of the vaginal dose to the
mbryos [62]. The signal appeared within minutes of vaginal appli-
ation, raising the possibility of direct transfer from the vagina to
he uterus, but the time courses of the signals were similar whether
osing was intravenous, subcutaneous, or intraperitoneal. Ligation
f the vagina near its apex did not prevent access of vaginally
dministered d-luciferin to the embryo, although transfer might
ave been delayed somewhat (Fig. 4). The experimental design
ould not quantify the amount of transfer to the embryo, only the
iming. The ﬁndings were consistent with systemic absorption and
istribution to the uterus or direct access from the vagina to the
terus through a countercurrent mechanism, because the vaginal
igation procedure was not believed to interfere with the vascu-
ar supply. Distribution by both a systemic and direct mechanism
ight also have been possible.
Pregnant rabbits were used to evaluate the transfer of intrav-
ginal thalidomide to the embryo [26]. Time-mated New Zealand
hite rabbits were treated orally or intravaginally on GD 7–11, theFig. 4. Mouse carrying embryos with luciferase-reporter transgene ∼6 min after
vaginal treatment with d-luciferin. The vagina has previously been ligated near its
apex. From Cao et al. [62], used by permission.
sensitive period for thalidomide-induced embryopathy. Animals
were monitored for vaginal leakage, which was minimal. In the
pharmacokinetic portion of this study, the oral dose levels were
20 or 180 mg/kg body weight (bw)/day, representing known oral
non-teratogenic and teratogenic dose levels, respectively. Vaginal
dose levels were 2, 20, or 180 mg/kg bw/day. The 2 mg/kg bw/day
dose level was more than four orders of magnitude higher than the
amount in human semen based on the known seminal distribution
of this medication at up to 250 ng/g of ejaculate after a 100-mg
dose [25]. Plasma exposures (area under the concentration-time
curve) by the vaginal route were 30% compared with oral dosing,
and maximum plasma concentrations were 3–7-fold lower by the
vaginal route. Yolk sac ﬂuid to plasma concentration ratios on GD
11 were similar (ranging from 0.49 to 0.66) across doses and routes
of administration, suggesting the absence of preferential transfer
from the vagina to the uterine contents.
In the embryo-fetal component of this study, pregnant
rabbits were treated orally or intravaginally with thalidomide
at 2 mg/kg bw/day on GD 7–19, and fetuses were evaluated
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Table 3
Maternal and fetal metronidazole after vaginal dosing of cynomolgus monkeys (from Thompson et al. [64]).
Metronidazole (ng/mL) Hydroxymetronidazole (ng/mL)
Dam ID Gestation day Maternal/fetal plasma Ratio Amniotic ﬂuid Maternal/fetal plasma Ratio Amniotic ﬂuid
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1503  71 494/539 0.9
n GD 29. A positive control group was given thalido-
ide at 180 mg/kg bw/day orally. Fetuses from does given
80 mg/kg bw/day orally had thalidomide-associated malforma-
ions typical for this species. There were no treatment-related
dverse fetal effects at 2 mg/kg bw/day by either the oral or vaginal
oute. The data indicate that thalidomide exposure from seminal
ransfer in the rabbit does not represent an embryo-fetal risk. Inas-
uch as the theoretical seminal dose of thalidomide in men  would
e four orders of magnitude lower than the tested vaginal dose in
abbits, thalidomide exposure from contact with semen would not
e expected to pose an embryo-fetal risk in human pregnancy.
In another experiment, three pregnant cynomolgus monkeys
ere given 1 mL  of 0.75% metronidazole gel intravaginally on
D 60, 70, or 71 using a commercial preparation formulated for
se in women [63,64]. There was minimal leakage after admin-
stration. Cesarean sections were performed 7 h after dosing, and
easurements of metronidazole and its hydroxylated metabolite
ere made in maternal and fetal blood samples and in amniotic
uid using tandem mass spectroscopy. Concentrations were similar
etween each mother and fetus, indicating no evidence of pref-
rential transfer to the fetus. Therefore, modeling using systemic
bsorption by the mother and distribution across the placenta
ould have been predictive of fetal exposure (Table 3).
.2. Monoclonal antibodies
Monoclonal antibody drugs are unlikely to be transferred to the
mbryo from semen in meaningful amounts based on the very low
oncentration of native immunoglobulins in semen and the lack of a
lacental receptor for immunoglobulin transfer early in pregnancy
29]. Empiric conﬁrmation of this principle has been reported in
abbits and monkeys.
After intravenous administration of a therapeutic IgG4 prod-
ct to male rabbits, semen concentrations were less than 1% of
hose in serum at all time points from 8 to 72 h after dosing [22].
ased on the concentration of IgG4 in semen and ejaculate vol-
me, the total dose delivered vaginally by seminal transmission
f the IgG4 would be 4–4.4 orders of magnitude lower than by
ntravenous dosing. Intravaginal administration of the antibody in
onpregnant females resulted in very low or undetectable serum
oncentrations. When equal doses were administered either vagi-
ally or intravenously, the highest detectable serum concentration
fter intravaginal dosing was 3.5 orders of magnitude lower than
he concentration in serum after intravenous dosing. On GD 29,
ntravenous IgG to pregnant rabbits resulted in fetal serum con-
entration 1.5-fold higher than maternal serum concentrations,
uggesting ready placental transfer at term. Based on the concen-
rations attainable in semen, the estimated fetal exposure on GD
9 from intravaginal semen from a male given 100 mg/kg bw intra-
enously was 3.5 × 10−5g/mL. This dose level was estimated to
esult in fetal exposures 1.3 × 10−8 times lower than administra-
ion of 100 mg/kg bw intravenously to the dam, a dose level not
xpected to be biologically meaningful.Pregnant cynomolgus monkeys were given an intravaginal dose
100 mg)  of a fully human IgG2 every two weeks from GD 21 to
D 133 [28]. Maternal plasma concentrations of the immunoglob-
lin were undetectable at all time points in 3 of 5 animals. In the5 3.66/4.17 0.9 2.01
9 26.5/21.1 1.3 8.69
7 19.6/21.3 0.9 13.4
remaining two animals, concentrations were low but measurable at
about half of the time points up to 120 h after dosing on GD 119 and
GD 133. The maximum maternal plasma concentration represented
0.01% of the intravaginal dose, about 4 orders of magnitude lower
than plasma concentrations after intravenous dosing. Cesarean sec-
tion was  performed 72 h after vaginal dosing on GD 133, but no
detectable antibody was present in the plasma of any fetus. The
low vaginal absorption in monkeys is consistent with the results
described above for the rabbit. Collectively, these data indicate that
seminal transfer does not represent an important exposure risk to
the embryo–fetus.
6.3. Peptides
Although no literature was  found on non-immunoglobulin pep-
tide or protein drugs being excreted in semen, there is evidence
that proteins of relevant size and structure are present in human
semen. For example, it has been shown that insulin-like growth
factor (IGF)-I and II, which share several structural and biological
features with insulin, are present in signiﬁcant amounts in seminal
plasma (IGF-I ∼0.1 g/mL, IGF-II ∼2 g/mL), and the presence of
IGF-1 is correlated with semen quality, suggesting a role in germ
cell maturation [65,66]. Because albumin concentrations in semi-
nal plasma are approximately half of those in blood plasma [11],
corresponding to interstitial concentrations, peptides with albu-
min  binding capacity will most likely not be up-concentrated in
seminal plasma.
Absorption of vaginally administered peptides is possible, but
bioavailability and potency are low compared to subcutaneous
administration [67,68] unless absorption enhancers or oleagi-
nous formulations are used as demonstrated with leuprolide,
a gonadotropin-releasing hormone analog [69–71], and insulin
[68–70,72,73]. Experimental administration of insulin per vagi-
nam to ovariectomized rats resulted in clear reductions in blood
glucose concentrations when insulin was  administered in combina-
tion with an enhancer of absorption (sodium taurodihydrofusidate,
polyoxyethylene-9-lauryl ether, lysophosphatidylcholine, palmi-
toylcarnitine chloride, or lysophosphatidylglycerol), while no effect
on blood glucose levels was  achieved when insulin was given with-
out an enhancer [68]. In another study, it was shown that the effect
on blood glucose concentrations in the rat was highly correlated
with the thickness of the vaginal epithelium with a higher effect in
metestrus and diestrus than estrus and pro-estrus [73]. Thickness
of the human vagina does not vary appreciably across the menstrual
cycle.
7. Conclusions
The hypothesis that vaginally administered medication will gain
access to the conceptus through the cervical canal is not supported
by available evidence. Transmission of chemicals to the oocyte by
binding to spermatozoa is theoretically possible, but quantitative
modeling does not suggest that clinically meaningful concentra-
tions can be achieved in the conceptus by this mechanism. Transfer
of medications absorbed via the vaginal epithelium into the venous
or lymphatic drainage of the vagina to the arterial supply of the
uterus has been demonstrated for few small molecule medications
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nd largely in nonpregnant subjects or in perfused hysterectomy
pecimens. Additional studies on possible transfer to the embryo
r fetus by this route would be welcome. Experimental animal
odels do not suggest that the theoretical alternative routes for
hemical transmission in semen will produce clinically meaningful
xposures of the conceptus.
Because large molecules reach semen in only low concen-
rations, modeling assumptions used for small molecules will
arkedly over-estimate possible exposure. Monoclonal antibody
ransmission in semen results in negligible exposures of sexual
artners and of the embryo and fetus. Vaginal peptidases and
enerally poor absorption across the vaginal epithelium will limit
ystemic access of seminal peptides. The available data on mono-
lonal antibody drugs indicate that vaginal absorption is extremely
ow.
The assumption that small-molecule pharmaceutical products
n semen will be 100% systemically absorbed during intercourse
ermits a reasonable and conservative approach to human risk
ssessment. The low seminal excretion and low vaginal absorp-
ion of monoclonal antibodies, combined with the small ejaculate
olume, would not result in biological meaningful exposure risk to
he conceptus, and assuming 100% systemic absorption of semi-
al peptides would result in a gross overestimate of embryo/fetal
xposure risk.
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